中国对阿斯利康前高管提起指控——这对全球制药企业意味着什么
AstraZeneca’s former China head has been formally charged with medical insurance fraud, illegal trading and unlawful collection of personal information, more than a year after he first came under investigation – casting a shadow over the Swedish-British drug maker’s expansion in its second-largest market.
The pharmaceutical giant confirmed to the Financial Times and Reuters that Leon Wang was one of two individuals indicted, as referenced in its latest earnings report published on Tuesday. The...
⚠️ 风险分析 高
摘要：阿斯利康前中国区高管因医保欺诈、非法交易及非法收集个人信息被正式起诉。
影响：事件为在华外企，特别是制药巨头，敲响数据合规与商业行为警钟，可能影响其在中国市场的扩张与运营。
建议：在华外企应紧急审查数据收集、医保报销及商业交易流程，强化合规体系与员工培训。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.